about
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaInsights into epigenetic regulation of microRNA-155 expression in multiple myelomaGene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individualsEvaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaDeregulation of DNA double-strand break repair in multiple myeloma: implications for genome stabilityCombining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regionsBortezomib is an efficient agent in plasma cell leukemias.Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.Monoclonal free light chains can be found in heavy chain diseases.Response to imatinib mesylate in patients with hypereosinophilic syndrome.Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival.Differentiation stage of myeloma plasma cells: biological and clinical significance.Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaTranscriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas.Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme.A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors.Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease featuresPhenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesCombination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rMicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders.Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Conventional diagnostics in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Molecular biology of myeloma.A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.Risk stratification in the era of novel therapies.Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance.Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.
P50
Q28074490-48C2952E-6429-4561-BAD8-1C51CFF6BADDQ28253748-96CF443B-D9C9-42C8-BF76-A833EBA1371BQ28285016-0EA3C3CC-BE2D-4198-92A6-C988EDB7A63BQ28296718-03432ED8-18EA-463A-AC4A-8B730B18C944Q28544696-1099D2D4-121C-4FBD-8B15-87230BD3450DQ30571858-52B04056-0AB4-42FF-AA12-DD107AA0CDF2Q33268092-3B9B3F96-29D8-4882-9714-477759B2A0EAQ33364213-722A48D1-E479-4882-B0B1-F85F981C5D6FQ33376498-0BFE5F3B-6B3D-4344-B995-52739F9ABD84Q33392209-EE8C3988-870D-4BFC-B46A-F53ED4F8AB7EQ33402403-6073AEC0-A732-4434-AACB-DA7FAE4C8744Q33705389-3B8781D5-54BE-4A21-A3D3-CD115419D32CQ33712516-292AE4D2-3D73-48EA-A97B-3077872886E4Q33816012-27550BF3-4BFF-4980-A191-3346D4296A1EQ33978937-2E34024D-4C66-4019-96F8-CFEA65952707Q34034713-D7B0F8CB-4965-490D-8D95-F632D44BE9D6Q34091328-B7CBA725-D32D-49A0-8588-BD90D32EA274Q34241661-D23B764D-444C-4D59-AEBC-F029D1D25458Q34259262-A5340065-6016-476C-9899-53348FE7DA2CQ34383712-C5696C04-5DE2-4243-9356-E69D162D2803Q34460989-9DBB537E-A7B7-4F26-9FD8-F415DA0207C9Q34543082-9724FC44-70C4-40CA-870B-838C23E5DF73Q35128148-43734D92-DC40-45B2-819A-20C36B4C4595Q35180069-3B968F17-C1C8-4AC9-AEF9-19A1E5756DA4Q35496723-C0C190FD-E312-4502-A938-5FCF1815E97BQ35842194-BF2F68D4-EC90-4925-A5C2-545815B55E42Q35944673-0CB1B713-AD4D-41CC-A80B-9D2D87C29A6AQ36133050-EA982079-C5D9-41E1-B9D8-5F7C2F13E7A6Q36498366-4B184574-B50A-4DC2-B392-0446D24C29E6Q36500714-3BFFAEF7-F67A-4494-A7A3-D7668ED8D2C6Q36595290-4ED0723B-95A1-47C3-8F2D-FA4EAE0CCE80Q36862536-8DC3FE59-D478-4E76-BCB7-1750434A0C6EQ36969778-5FE02375-6D78-4F12-A3A5-6F8EF5D41794Q36987485-9B20AEA7-2C56-464A-B5A5-4AB5AE476CD7Q37112857-44D646BF-E9A4-4F93-89FB-33ED5F8546F5Q37564751-37AC5D64-9E59-4ABF-B534-B8C16FA10506Q37654397-3EAA3F8E-30F1-484F-9EED-9AF6F9C1FFCDQ38331348-4FD8DB72-BE85-4297-A940-C9004CD39ECFQ38484493-D8B626F9-614A-4FB8-BD6D-072711176B8BQ38645307-1382F5A6-A5AB-4EA1-B4A5-49BD49E80B92
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Norma C Gutiérrez
@nl
Norma C Gutiérrez
@sl
Norma C. Gutiérrez
@en
Norma C. Gutiérrez
@es
type
label
Norma C Gutiérrez
@nl
Norma C Gutiérrez
@sl
Norma C. Gutiérrez
@en
Norma C. Gutiérrez
@es
prefLabel
Norma C Gutiérrez
@nl
Norma C Gutiérrez
@sl
Norma C. Gutiérrez
@en
Norma C. Gutiérrez
@es
P106
P1153
7004008320
P21
P31
P3835
norma-gutierrez
P496
0000-0001-5834-9510